Medicine and Dentistry
Hodgkin's Lymphoma
97%
Autologous Stem Cell Transplantation
79%
Rituximab
77%
Classical Hodgkin Lymphoma
71%
Non-Hodgkin Lymphoma
71%
Diffuse Large B-Cell Lymphoma
64%
Positron Emission Tomography
56%
CHOP
50%
Disease
49%
Drug Megadose
48%
Burkitt's Lymphoma
42%
Radiation Therapy
41%
Posttransplant Lymphoproliferative Disease
40%
Neoplasm
34%
Tumor Cell
33%
Human Leukocyte Antigen
30%
Sjoegren Syndrome
30%
Hazard Ratio
30%
Epstein Barr Virus
30%
Arm
28%
Central Nervous System
28%
Doxorubicin
28%
Overall Survival
26%
Cyclophosphamide
23%
MALT Lymphoma
22%
Prognostic Factor
22%
Epstein-Barr Virus
22%
Lymphoma
22%
Autologous Bone Marrow Transplantation
22%
Oncology
22%
Progression Free Survival
21%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Immune Checkpoint Inhibitor
20%
Waldenström's Macroglobulinemia
20%
Granulocyte Colony Stimulating Factor
20%
B-Cell Lymphoma
20%
Reed-Sternberg Cell
20%
Acute Myeloid Leukemia
20%
Event Free Survival
20%
Etoposide
19%
Cytarabine
17%
Methotrexate
17%
B Cell
16%
Vincristine
16%
Progressive Disease
15%
Fluorodeoxyglucose F 18
15%
Side Effect
14%
Disease Specific Survival
14%
Testis Cancer
14%
Disease Free Survival
14%
Immunology and Microbiology
B Cell
100%
Epstein Barr Virus
95%
Autologous Stem Cell Transplantation
66%
Drug Megadose
59%
Rituximab
58%
Positron Emission Tomography
57%
Overall Survival
54%
Cyclophosphamide
53%
Progression Free Survival
43%
Event Free Survival
38%
Arm
37%
Bone Marrow Transplantation
36%
Thymus and Activation Regulated Chemokine
35%
Human Leukocyte Antigen
30%
Central Nervous System
27%
Disease Free Survival
27%
Blood Plasma
26%
Transplant Procedure
25%
Tumor Cell
22%
Human Immunodeficiency Virus
22%
Prednisone
20%
Viral Disease
20%
Granulocyte Colony-Stimulating Factor
20%
Lymphocyte
20%
Reed Sternberg Cell
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
19%
Conditioning
17%
Allogeneic Stem Cell Transplantation
16%
Methotrexate
15%
Hematopoietic Stem Cell Transplantation
15%
Solid Organ Transplantation
15%
Leukocyte Count
15%
Platelet
15%
Germinal Center
13%
Graft-Versus-Host Disease
13%
DNA Virus
12%
Hodgkin Lymphoma Cell Line
12%
Lymphoproliferative Disorders
11%
Prednisolone
10%
Lenalidomide
10%
Insulin-Like Growth Factor 1 Receptor
10%
Ganglioside GM1 Antibody
10%
Hepatic Portal Vein
10%
Antigen Presentation
10%
Promyelocytic Leukemia Protein
10%
Hepatitis E Virus
10%
Genome-Wide Association Study
10%
Peripheral Blood Stem Cell Transplantation
10%
Autologous Peripheral Blood Stem Cell Transplantation
10%
Multiple Myeloma
10%
Keyphrases
Aggressive non-Hodgkin Lymphoma
40%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
35%
Lymphoma Patients
34%
Poor Risk
30%
Classical Hodgkin Lymphoma
30%
High Dose
25%
Dutch
23%
Belgian
22%
Oncohematology
22%
Overall Survival
21%
CHOP Chemotherapy
21%
Transplantation
20%
Post-transplant Lymphoproliferative Disorder
20%
Burkitt Lymphoma
20%
Allogeneic Bone Marrow Transplantation
20%
Slow Response
20%
Marrow Transplantation
20%
Cooperative Group
20%
Relapsed or Refractory Diffuse Large B-cell Lymphoma
20%
Alemtuzumab
20%
Peripheral T-cell Lymphoma
20%
Thymus
20%
Activation-regulated Chemokine
20%
Waldenström Macroglobulinemia
20%
Acute Myeloid Leukemia
20%
Disease-free Survival
19%
Event-free Survival
19%
Lymphoma
19%
Rituximab
19%
Confidence Interval
17%
Chemotherapy
16%
Phase II Trial
16%
Marrow
15%
CHOP Therapy
15%
Fast Response
15%
Chemoradiotherapy
15%
Treatment Response
14%
Diffuse Large B-cell Lymphoma (DLBCL)
13%
Hematopoietic Stem Cell Transplantation
12%
Sequential Therapy
12%
Working Party
12%
Clinical Presentation
12%
Epstein-Barr Virus DNA Load
12%
R-CHOP
11%
Cyclophosphamide
11%
F-18 Fluorodeoxyglucose Positron Emission Tomography
11%
Doxorubicin
11%
Reduced-intensity Conditioning
11%
Allograft
11%
Response Evaluation
11%